JonesTrading Thinks Actinium Pharmaceuticals’ Stock is Going to Recover

JonesTrading analyst Soumit Roy reiterated a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report) today and set a price target of $40.00. The company’s shares closed last Wednesday at $6.85, close to its 52-week low of $5.70.

According to, Roy is a 5-star analyst with an average return of 34.8% and a 46.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Monopar Therapeutics Inc, and Adaptimmune Therapeutics.

Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $42.50.

See today’s analyst top recommended stocks >>

Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $266K and GAAP net loss of $5.02 million. In comparison, last year the company had a GAAP net loss of $4.63 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.